Orange Backs Guidance After Revenue, Earnings Match Views
By Adria Calatayud
Orange confirmed its 2023 outlook after it reported revenue and earnings for the third quarter that rose slightly and were broadly in line with consensus expectations.
The French telecommunications group said Tuesday that revenue for the quarter was 11.00 billion euros ($11.74 billion), up 1.6% on year. Growth in the company's retail operations offset a decline in wholesale revenue, Orange said.
The company's earnings before interest, taxes, depreciation and amortization after leases came in 0.4% higher at EUR3.60 billion. Orange said Ebitda after leases grew 1.4% on a comparable basis, accelerating from 1% in the second quarter, which it attributed to cost savings.
Analysts expected the company to report quarterly Ebitda after leases of EUR3.59 billion on revenue of EUR11.00 billion, according to consensus estimates provided by Orange.
Orange confirmed its 2023 outlook, which contemplates Ebitda after leases growing slightly and a significant reduction in capital expenditure among other targets.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
October 24, 2023 01:47 ET (05:47 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks